| Identification | Back Directory | [Name]
N-[(6-Hydroxy-1-naphthyl)carbamothioyl]-2-furamide | [CAS]
827001-82-1 | [Synonyms]
5J 4
N-[(6-Hydroxy-1-naphthyl)carbamothioyl]-2-furamide
2-Furancarboxamide, N-[[(6-hydroxy-1-naphthalenyl)amino]thioxomethyl]-
Inhibitor,Calcium release-activated channels,CRAC Channel,CNS,Ca2+ release-activated Ca2+ channels,5J 4,inflammation,5J4,inhibit,CD4+ cells,mononuclear cell,experimental autoimmune encephalomyelitis,5J-4 | [Molecular Formula]
C16H12N2O3S | [MDL Number]
MFCD05832424 | [MOL File]
827001-82-1.mol | [Molecular Weight]
312.34 |
| Chemical Properties | Back Directory | [density ]
1.459±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [pka]
8.08±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
N-[[(6-Hydroxy-1-naphthalenyl)amino]thioxomethyl]-2-furancarboxamide inhibits or blocks the calcium release-activated calcium (CRAC) channel for alleviation of autoimmune diseases. | [Biological Activity]
Primary Target
Orail1 | [in vivo]
5J-4 reduces the production of IL-17 and decreases the expression of RORα and RORγt[1].
5J-4 (2 mg/kg; i.p.; every alternate day for 30 days) reduces the symptoms and delayed the onset of EAE[1]. | Animal Model: | C57BL/6 mice (MOG35-55 peptide-immunized mice)[1] | | Dosage: | 2 m/kg | | Administration: | I.p., every alternate day for 30 days | | Result: | Dramatically reduced the symptoms and delayed the onset of EAE and decreased the numbers of infiltrated mononuclear cell into the CNS, and significantly decreased the population of infiltrated CD4+ population. |
| [storage]
Store at -20°C |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Specs
|
| Tel: |
+31 15 251 8111 |
| Website: |
www.specs.net |
|